Status:
COMPLETED
Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors
Lead Sponsor:
Kyowa Kirin, Inc.
Collaborating Sponsors:
AstraZeneca
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Mogamulizumab in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Eligibility Criteria
Inclusion
- Age ≥ 18 years;
- Locally advanced or metastatic solid tumors;
- Histologically or cytologically confirmed disease;
- Failed or were intolerant to at least one prior systemic treatment regimen with oral or IV medications and have no additional therapy options known to prolong survival with the exception of PD-1 or PD-L1 blockade therapy for subjects who will be enrolled in treatment arm A. Subjects with non-small cell lung cancer must have received at least one platinum doublet regimen. Subjects with known epidermal growth factor receptor tyrosine kinase inhibitor activating mutations or anaplastic lymphoma kinase rearrangement must have also exhausted approved targeted therapy options;
- The subject has a tumor suitable for biopsy and is willing to undergo tumor biopsy, preferably of the primary tumor, within 28 days prior to Cycle 1/Visit Day 1;
Exclusion
- Any concurrent chemotherapy, biologic, hormonal, radiation, or investigative therapy for cancer treatment within 21 days prior prior or within 6 weeks prior to Cycle 1/Visit Day 1 for nitrosoureas or mitomycin C;
- Concurrent or prior use of immunosuppressive medication within 28 days;
- Active or prior documented autoimmune, or inflammatory bowel disease, or inflammatory bowel disease. or systemic treatment for psoriasis within the past 5 years.;
- Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins, or immunotherapy.
Key Trial Info
Start Date :
November 26 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 5 2018
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT02301130
Start Date
November 26 2014
End Date
March 5 2018
Last Update
April 25 2024
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
The Angeles Clinic
Los Angeles, California, United States, 90025
2
UCLA Hematology & Oncology Clinic
Los Angeles, California, United States, 90095
3
Yale Cancer Center
New Haven, Connecticut, United States, 06520-8028
4
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612